Senores Pharma Eyes ₹250 Cr Revenue by FY28 Post Apnar Acquisition

• Senores Pharma expects revenue from its Apnar Pharma acquisition to reach ₹250 crore by FY28, up from ₹120 crore in FY27.
• The ₹91 crore acquisition includes five Abbreviated New Drug Applications (ANDAs) with existing government business and a US manufacturing base.
• The Apnar facility holds approvals from US FDA, UK MHRA, and Health Canada, providing immediate business traction and regulatory compliance.
• Promoter Swapnil Shah highlights the deal as value-accretive, offering operational products, customer relationships, and margin accretion from day one.
• The manufacturing unit's capacity of 275 million units, expandable to 400 million, supports significant revenue scaling without major additional capex.

Why It Matters: Apnar acquisition positions Senores Pharma for significant revenue growth and strengthens its US market presence.